FDA Approves Incivek™ (Telaprevir) for Hepatitis C, Genotype 1
With the approval of Incivek™ (telaprevir) by the FDA on May 23rd, combination therapy treatment time could be cut in half for many Hepatitis C, genotype 1 patients.
Continue reading »Hepatitis C Treatments/Therapies
Victrelis™ (Boceprevir): The New Hepatitis C Drug
With the approval of Victrelis™ (boceprevir) for the treatment of those with Hepatitis C, genotype 1, many questions arise. Here we have summarized some of these questions.
Continue reading »Could New HCV Drugs Excessive Pill Intake Hinder Compliance?
Since Victrelis™ (boceprevir) is to be administered in combination with peginterferon alfa and ribavirin to treat chronic Hepatitis C genotype 1 infection, taking so many medications could cause compliance issues. However, there may be other options.
Continue reading »Boceprevir Approval Means Better Hep C Treatment Finally Available
As the first FDA approved Hepatitis C protease inhibitor, boceprevir (Victrelis) has cleared the final hurdle and can now improve the general public's odds for beating the Hepatitis C virus.
Continue reading »May 23 Could Bring Approval for Vertex's Hep C Drug
Due to a solid Phase III program, Vertex's telaprevir (Incivek) could receive approval to treat Hepatitis C before the end of May 2011.
Continue reading »FDA Backs Telaprevir for Having High Hepatitis C Cure Rate
Just a day after doling out similar praise for a comparable drug from Merck, an FDA panel backed the approval of Vertex's telaprevir, largely due to their computation that this drug's Hepatitis C cure rate goes far beyond the current therapy's ability.
Continue reading »Phase III Trials Begin for Boehringer's Hepatitis C Drug
May 3, 2011
1 Comment
Enrolling 1,875 patients with chronic genotype-1 Hepatitis C, Boehringer will begin three phase III trials for BI 201335, an oral protease inhibitor.
Continue reading »Encouraging News for Hepatitis C Vaccine
Preliminary phase I data for a therapeutic T-cell Hepatitis C vaccine posts hopeful results.
Continue reading »Telaprevir's Chemistry Speeds HCV Treatment Time
Upon further study of telaprevir, researchers have determined that it may dramatically shorten the time required for successful Hepatitis C therapy.
Continue reading »Bristol-Myers Experimental Cocktail Bests Hepatitis C Treatment
Without pegylated interferon, experimental drugs by Bristol-Myers Squibb appear to be on the path of improving Hepatitis C treatment - by making it easier to endure and increasing the success rate.
Continue reading »
